Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/04/2022* -- Results Q3 2022 -- -1.29 --
11/04/2022* 08:00 EST Earnings Call Q3 2022 -- -- --
08/04/2022 -- Results Q2 2022 -1.33 -1.30 -2.43%
08/04/2022 08:00 EST Earnings Call Q2 2022 -- -- --
05/05/2022 -- Results Q1 2022 -1.96 -1.11 -76.41%
05/05/2022 08:00 EST Earnings Call Q1 2022 -- -- --
02/24/2022 -- Results Q4 2021 -1.09 -0.94 -16.34%
02/24/2022 08:00 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 11/04/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/04/2022
Beat/Miss Upgrade
Return Since -14.37%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
URL https://www.intelliatx.com
Investor Relations URL https://ir.intelliatx.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Nov. 04, 2022 (est.)
Last Earnings Release Aug. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
--
46.61%
-28.98%
7.47%
270.8%
117.4%
-52.61%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-22.58%
32.33%
-32.38%
2.42%
-0.65%
0.53%
28.66%
30.72%
10.05%
-29.63%
-52.07%
-43.76%
-71.37%
-38.63%
70.63%
-53.49%
-75.14%
--
--
-0.37%
-2.63%
-64.63%
-4.83%
206.3%
-50.19%
15.38%
1.56%
-35.67%
-38.44%
161.9%
-17.93%
-19.28%
-52.23%
As of September 27, 2022.

Profile

Edit
Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
URL https://www.intelliatx.com
Investor Relations URL https://ir.intelliatx.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Nov. 04, 2022 (est.)
Last Earnings Release Aug. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
ADNRX 16.16M USD 5.26%
IDNA 8.159M USD 4.90%
ARKK 362.63M USD 4.88%
GNOM 9.216M USD 4.68%
EARK.NO 3.757M USD 4.56%
ARKG 99.16M USD 4.29%
CARKAX 385.00 USD 3.85%
KRXCX 517600.0 USD 2.86%
YOVAX 762762.0 USD 1.98%
FBIOX 57.31M USD 1.14%
FKBSX 51.09M USD 1.06%
BBH 3.379M USD 0.82%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter NTLA Tweets